Hims & Hers Health (HIMS) Projected to Post Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is projected to issue its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect the company to announce earnings of $0.09 per share and revenue of $578.9920 million for the quarter. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 3, 2025 at 5:00 PM ET.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health’s revenue was up 72.6% on a year-over-year basis. During the same period last year, the firm earned $0.06 earnings per share. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $48.86 on Monday. The stock’s 50-day moving average is $51.14 and its two-hundred day moving average is $49.80. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health has a 1 year low of $18.33 and a 1 year high of $72.98. The firm has a market cap of $11.04 billion, a price-to-earnings ratio of 61.07, a PEG ratio of 3.38 and a beta of 2.25.

Insider Activity

In related news, CEO Andrew Dudum sold 660,000 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares of the company’s stock, valued at $112,023,016.02. This represents a 22.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 145,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the completion of the sale, the chief financial officer owned 128,984 shares of the company’s stock, valued at approximately $7,139,264.40. The trade was a 52.92% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,429,634 shares of company stock valued at $74,097,471. 17.71% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its holdings in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health during the first quarter worth $30,000. Palisade Capital Management LP purchased a new stake in Hims & Hers Health during the second quarter worth $224,000. SkyView Investment Advisors LLC acquired a new stake in Hims & Hers Health during the 2nd quarter valued at $226,000. Finally, Meiji Yasuda Asset Management Co Ltd. purchased a new position in Hims & Hers Health during the second quarter worth $234,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HIMS has been the topic of a number of research reports. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Hims & Hers Health in a research report on Tuesday, October 14th. KeyCorp started coverage on shares of Hims & Hers Health in a research note on Tuesday, October 21st. They set a “sector weight” rating for the company. Finally, Truist Financial dropped their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research note on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Reduce” and a consensus price target of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.